"In addition to finding winning stock picks, this newsletter is also great at educating about how to trade and how wall street works. I am new to investing on my own. The trades are easy to follow, Read more...
Is he fit to write anything on BIOs?
"Most of the companies are run by well qualified scientists and administrative personal. Prior to commenting on anything, the guy should be either qualified or experienced on the Subject matter. Adam has neither of this traits. In my opinion he and his boss Jim Creamer uses the Media & CNBC to Read more...
No Science background
I can't understand why traders here don't look at his education background. Where does it say he has bio-med training? He's done real estate in SF... how does that give him the expertise to analyse biogen?
Timing is questionable
The timing of his reviews are very interesting. He blasts a stock, it plummets then returns.....someone is benefiting and doesn't seem to be a coincidence. From previous reviewers, it appears I am not alone in noticing this trend. Wouldn't be surprised if he was or will be investigated. I would take Read more...
I don't trust a word he writes. His timing is suspect.
He writes for the.street. No serious investor I know makes decisions based on the reporting there. I would consider his recommendations with a shaker of salt.
"Even if you don't like him, you can't miss him. If you don't read his articles, you won't get what biotechs are in the picture at that particular moment in time. Don't trade what he likes, but you can use to invest. He is not a trader, but he has a solid fundamental understanding of biotechs. Some Read more...
Good Basic Reporting
Adam provides in-depth coverage on an array of biotech stocks. Although his reporting doesn't provide much analysis of the impact of news on stock price, it's useful from a basic reporting perspective to any biotech trader/investor. He seems a constant sceptic and able to bring to light some of the Read more...
Don't let my title for Adam fool you, I like this guy. He is essential reading for anyone looking to make some side dough, let alone a living, playing the biotech sector. Lots of people hate the guy, only because they are rookie speculators that didn't do their dd on a stock he probably tore the p Read more...
"First of all, Feuerstein works for Jim Cramer. If that isn't a big enough red flag, he isn't even a real stock analyst or journalist. He posts merely for entertainment purposes. That being said, he loves to put out incredibly bearish articles about small biotech companies in an effort to drive the Read more...